Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysis

References

• Levin A, Tonelli M, Bonventre J, et al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet. 2017;390(10105):1–16.
   PubMed Web of Science ®Google Scholar
• Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the global burden of disease study 2017. The Lancet. 2020;395(10225):709–733.
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305.
   PubMed Web of Science ®Google Scholar
• Huang Y, Xin W, Xiong J, et al. The intestinal microbiota and metabolites in the gut-kidney-heart axis of chronic kidney disease. Front Pharmacol. 2022;13:837500.
   PubMed Web of Science ®Google Scholar
• Bennett B, Vallim T, Wang Z, et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013;17(1):49–60. 10.1016/j.cmet.2012.12.011.
   PubMed Web of Science ®Google Scholar
• Sumida K, Kovesdy CP. The gut-kidney-heart axis in chronic kidney disease. Physiol Int. 2019;106(3):195–206.
   PubMed Web of Science ®Google Scholar
• Zhao J, Ning X, Liu B, et al. Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review. Ren Fail. 2021;43(1):102–112.
   PubMed Web of Science ®Google Scholar
• Cosola C, Rocchetti MT, Sabatino A, et al. Microbiota issue in CKD: how promising are gut-targeted approaches? J Nephrol. 2019;32(1):27–37.
   PubMed Web of Science ®Google Scholar
• Noce A, Marchetti M, Marrone G, et al. Link between gut microbiota dysbiosis and chronic kidney disease. Eur Rev Med Pharmacol Sci. 2022;26(6):2057–2074.
   PubMed Web of Science ®Google Scholar
• Wu R, Ruan X-L, Ruan D-D, et al. Differences in gut microbiota structure in patients with stages 4-5 chronic kidney disease. Am J Transl Res. 2021;13(9):10056–10074.
   PubMed Web of Science ®Google Scholar
• Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–585.
   PubMed Web of Science ®Google Scholar
• Tang WHW, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–1584.
   PubMed Web of Science ®Google Scholar
• Xu K-Y, Xia G-H, Lu J-Q, et al. Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients. Sci Rep. 2017;7(1):1445.
   PubMed Web of Science ®Google Scholar
• Lau WL, Savoj J, Nakata MB, et al. Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins. Clin Sci (Lond). 2018;132(5):509–522.
   PubMed Web of Science ®Google Scholar
• Bain MA, Faull R, Fornasini G, et al. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing hemodialysis. Nephrol Dial Transplant. 2006;21(5):1300–1304.
   PubMed Web of Science ®Google Scholar
• Boini KM, Hussain T, Li P-L, et al. Trimethylamine-N-oxide instigates NLRP3 inflammasome activation and endothelial dysfunction. Cell Physiol Biochem. 2017;44(1):152–162.
   PubMedGoogle Scholar
• Ma G, Pan B, Chen Y, et al. Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion. Biosci Rep. 2017;37(2):BSR20160244.
   Google Scholar
• Seldin MM, Meng Y, Qi H, et al. Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB. J Am Heart Assoc. 2016;5(2):e002767.
   PubMed Web of Science ®Google Scholar
• Sun X, Jiao X, Ma Y, et al. Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome. Biochem Biophys Res Commun. 2016;481(1-2):63–70.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Tang Z, You L, et al. Trimethylamine-N-oxide is an independent risk factor for hospitalization events in patients receiving maintenance hemodialysis. Ren Fail. 2020;42(1):580–586.
   PubMed Web of Science ®Google Scholar
• Robinson-Cohen C, Newitt R, Shen DD, et al. Association of FMO3 variants and trimethylamine N-oxide concentration, disease progression, and mortality in CKD patients. PLoS One. 2016;11(8):e0161074.
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. [Internet]. Ottawa: Ottawa Hospital Research Institute; 2000. [Cited 2020 Dec 31]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
   Google Scholar
• Rostom A, Dubé C, Cranney A, et al. Celiac disease (evidence reports/technology assessments, No. 104). Appendix D. Quality assessment forms. [Internet]. Rockville (MD): Agency for Healthcare Research and Quality; 2004. [Cited 2020 Dec 31]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK35156/.
   Google Scholar
• Cooper H, Hedges LV, editors. Handbook of research synthesis. New York (NY): Russell Sage Foundation; 1994.
   Google Scholar
• Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549.
   PubMed Web of Science ®Google Scholar
• Julian PT Higgins and Sally Green. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Vol. 2011;2:126–130. editor
   Google Scholar
• Tang WHW, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–455.
   PubMed Web of Science ®Google Scholar
• Kaysen GA, Johansen KL, Chertow GM, et al. Associations of trimethylamine N-oxide with nutritional and inflammatory biomarkers and cardiovascular outcomes in patients new to dialysis. J Ren Nutr. 2015;25(4):351–356.
   PubMed Web of Science ®Google Scholar
• Stubbs JR, House JA, Ocque AJ, et al. Serum trimethylamine-N-oxide is elevated in CKD and correlates with coronary atherosclerosis burden. J Am Soc Nephrol. 2016;27(1):305–313.
   PubMed Web of Science ®Google Scholar
• Missailidis C, Hällqvist J, Qureshi AR, et al. Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLoS ONE. 2016;11(1):e0141738.
   PubMed Web of Science ®Google Scholar
• Mafune A, Iwamoto T, Tsutsumi Y, et al. Associations among serum trimethylamine-N-oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study. Clin Exp Nephrol. 2016;20(5):731–739.
   PubMed Web of Science ®Google Scholar
• Kim RB, Morse BL, Djurdjev O, et al. Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. Kidney Int. 2016;89(5):1144–1152.
   PubMed Web of Science ®Google Scholar
• Al-Obaide MAI, Singh R, Datta P, et al. Gut microbiota-dependent trimethylamine-N-oxide and serum biomarkers in patients with T2DM and advanced CKD. J Clin Med. 2017;6(9):86.
   PubMed Web of Science ®Google Scholar
• Gruppen EG, Garcia E, Connelly MA, et al. TMAO is associated with mortality: impact of modestly impaired renal function. Sci Rep. 2017;7(1):13781.
   PubMedGoogle Scholar
• Zhang L, Xie F, Tang H, et al. Gut microbial metabolite TMAO increases peritoneal inflammation and peritonitis risk in peritoneal dialysis patients. Transl Res. 2022;240:50–63.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zou J-Z, Chen J, et al. Association of trimethylamine N-oxide with cardiovascular and all-cause mortality in hemodialysis patients. Ren Fail. 2020;42(1):1004–1014.
   PubMed Web of Science ®Google Scholar
• Fu D, Shen J, Li W, et al. Elevated serum trimethylamine N-oxide levels are associated with mortality in male patients on peritoneal dialysis. Blood Purif. 2021;50(6):837–847.
   PubMed Web of Science ®Google Scholar
• Chang D, Xu X, Yang Z, et al. Trimethylamine-N-oxide (TMAO) and clinical outcomes in patients with end-stage kidney disease receiving peritoneal dialysis. Perit Dial Int. 2022;42(6):622–630.
   PubMed Web of Science ®Google Scholar
• Shafi T, Powe NR, Meyer TW, et al. Trimethylamine N-oxide and cardiovascular events in hemodialysis patients. J Am Soc Nephrol. 2017;28(1):321–331.
   PubMed Web of Science ®Google Scholar
• Stubbs JR, Stedman MR, Liu S, et al. Trimethylamine N-oxide and cardiovascular outcomes in patients with ESKD receiving maintenance hemodialysis. Clin J Am Soc Nephrol. 2019;14(2):261–267.
   PubMed Web of Science ®Google Scholar
• Sapa H, Gutiérrez OM, Shlipak MG, et al. Association of uremic solutes with cardiovascular death in diabetic kidney disease. Am J Kidney Dis. 2022;80(4):502–512.e1.
   PubMed Web of Science ®Google Scholar
• Winther SA, Øllgaard JC, Tofte N, et al. Utility of plasma concentration of trimethylamine N-oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes. Diabetes Care. 2019;42(8):1512–1520.
   PubMed Web of Science ®Google Scholar
• Winther SA, Øllgaard JC, Hansen TW, et al. Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. PLoS One. 2021;16(3):e0244402.
   PubMed Web of Science ®Google Scholar
• Hernandez L, Ward LJ, Arefin S, et al. Blood-brain barrier and gut barrier dysfunction in chronic kidney disease with a focus on circulating biomarkers and tight junction proteins. Sci Rep. 2022;12(1):4414.
   PubMed Web of Science ®Google Scholar
• El-Deeb OS, Atef MM, Hafez YM. The interplay between microbiota-dependent metabolite trimethylamine N-oxide, transforming growth factor β/SMAD signaling and inflammasome activation in chronic kidney disease patients: a new mechanistic perspective. J Cell Biochem. 2019;120(9):14476–14485.
   PubMed Web of Science ®Google Scholar
• Li D, Lu Y, Yuan S, et al. Gut microbiota-derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis. Am J Clin Nutr. 2022;116(1):230–243.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Guo M, Fang X, et al. Gut microbiota-derived trimethylamine N-oxide and kidney function: a systematic review and meta-analysis. Adv Nutr. 2021;12(4):1286–1304.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Jin H, Ju H, et al. Circulating trimethylamine-N-oxide and risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and meta-analysis. Front Med. 2022;9:828343.
   Web of Science ®Google Scholar
• Gupta N, Buffa JA, Roberts AB, et al. Targeted inhibition of gut microbial trimethylamine N-Oxide production reduces renal tubulointerstitial fibrosis and functional impairment in a murine model of chronic kidney disease. Arterioscler Thromb Vasc Biol. 2020;40(5):1239–1255.
   PubMed Web of Science ®Google Scholar
• Zhang W, Miikeda A, Zuckerman J, et al. Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice. Sci Rep. 2021;11(1):518.
   PubMed Web of Science ®Google Scholar
• Kapetanaki S, Kumawat AK, Persson K, et al. The fibrotic effects of TMAO on human renal fibroblasts is mediated by NLRP3, caspase-1 and the PERK/akt/mTOR pathway. Int J Mol Sci. 2021;22(21):11864.
   PubMed Web of Science ®Google Scholar
• Din AU, Hassan A, Zhu Y, et al. Amelioration of TMAO through probiotics and its potential role in atherosclerosis. Appl Microbiol Biotechnol. 2019;103(23-24):9217–9228.
   PubMed Web of Science ®Google Scholar
• Janeiro MH, Ramírez MJ, Milagro FI, et al. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. Nutrients. 2018;10(10):1398.
   PubMed Web of Science ®Google Scholar
• Yang S, Li X, Yang F, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: inflammation mechanism, clinical prognostic, and potential as a therapeutic target. Front Pharmacol. 2019;10:1360.
   PubMed Web of Science ®Google Scholar
• Zhang L, Nie J, Zhang X. Fo044gut microbiota metabolite trimethylamine-N-oxide aggravates peritoneal inflammation via activating nlrp3-caspase 1 pathway. Nephrol Dial Transplant. 2019;34(Supplement_1):i20–i22.
   Web of Science ®Google Scholar
• Xie Y, Hu X, Li S, et al. Pharmacological targeting macrophage phenotype via gut-kidney axis ameliorates renal fibrosis in mice. Pharmacol Res. 2022;178:106161.
   PubMed Web of Science ®Google Scholar
• Lai Y, Tang H, Zhang X, et al. Trimethylamine-N-oxide aggravates kidney injury via activation of p38/MAPK signaling and upregulation of HuR. Kidney Blood Press Res. 2022;47(1):61–71.
   PubMedGoogle Scholar
• Zhu W, Gregory JC, Org E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–124.
   PubMed Web of Science ®Google Scholar
• Makrecka-Kuka M, Volska K, Antone U, et al. Trimethylamine N-oxide impairs pyruvate and fatty acid oxidation in cardiac mitochondria. Toxicol Lett. 2017;267:32–38.
   PubMed Web of Science ®Google Scholar
• Ku E, Yang W, McCulloch CE, et al. Race and mortality in CKD and dialysis: findings from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2020;75(3):394–403.
   PubMed Web of Science ®Google Scholar
• Mitchell SM, Milan AM, Mitchell CJ, et al. Protein intake at twice the RDA in older men increases circulatory concentrations of the microbiome metabolite Trimethylamine-N-Oxide (TMAO). Nutrients. 2019;11(9):2207.
   PubMed Web of Science ®Google Scholar
• Mafra D, Black Veiga AP, Saraiva dos Anjos J, et al. Mp449effect of low protein diet on trimethylamine-N-oxide plasma levels in non-dialysis chronic kidney disease patients. Nephrol Dial Transplant. 2017;32(suppl_3):iii593–iii594.
   Google Scholar
• Borges NA, Stenvinkel P, Bergman P, et al. Effects of probiotic supplementation on trimethylamine-N-Oxide plasma levels in hemodialysis patients: a pilot study. Probiotics Antimicrob Proteins. 2019;11(2):648–654.
   PubMed Web of Science ®Google Scholar
• Wang S, Lv D, Jiang S, et al. Quantitative reduction in short-chain fatty acids, especially butyrate, contributes to the progression of chronic kidney disease. Clin Sci. 2019;133(17):1857–1870.
   Web of Science ®Google Scholar
• Liu J, Lai L, Lin J, et al. Ranitidine and finasteride inhibit the synthesis and release of trimethylamine N-oxide and mitigates its cardiovascular and renal damage through modulating gut microbiota. Int J Biol Sci. 2020;16(5):790–802.
   PubMed Web of Science ®Google Scholar
• Ji C, Li Y, Mo Y, et al. Rhubarb enema decreases circulating trimethylamine N-oxide level and improves renal fibrosis accompanied with gut microbiota change in chronic kidney disease rats. Front Pharmacol. 2021;12:780924.
   PubMed Web of Science ®Google Scholar
• Liu X, Tan Z, Huang Y, et al. Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis. Cardiovasc Diabetol. 2022;21(1):124. Jul 1
   PubMed Web of Science ®Google Scholar
• Hill E, Sapa H, Negrea L, et al. Effect of oat β-glucan supplementation on chronic kidney disease: a feasibility study. J Ren Nutr. 2020;30(3):208–215.
   PubMed Web of Science ®Google Scholar
• Yang W, Zhang S, Zhu J, et al. Gut microbe-derived metabolite trimethylamine N-oxide accelerates fibroblast-myofibroblast differentiation and induces cardiac fibrosis. J Mol Cell Cardiol. 2019;134:119–130.
   PubMed Web of Science ®Google Scholar
• Integrative HMP (iHMP) Research Network Consortium. The integrative human microbiome project. Nature. 2019;569(7758):641–648.
   PubMed Web of Science ®Google Scholar